Want to see CGON full AI Analyst Report?
CGON Stock Chart & Stats
$78.95
$2.37(3.42%)
At close: 4:00 PM EDT
$78.95
$2.37(3.42%)
Day’s Range― - ―
52-Week Range$35.80 - $80.97
Previous Close$30.46
Volume104.85K
Average Volume (3M)963.47K
Market Cap
$5.31B
Enterprise Value$5.25B
Total Cash (Recent Filing)$1.03B
Total Debt (Recent Filing)$8.82M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Nov 12, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding88,640,370
10 Day Avg. Volume928,857
30 Day Avg. Volume963,474
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.26
Price to Sales (P/S)794.47
P/FCF Ratio-24.23
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue842.51
Enterprise Value/Gross Profit-1.02K
Enterprise Value/Ebitda-23.70
Forecast
1Y Price Target
$92.56Price Target Upside17.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.28
Revenue Forecast (FY)$4.31M
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityThe approximately $1.0 billion cash, equivalents, and marketable securities balance gives CG Oncology meaningful funding visibility through 2029. This reduces near-term financing pressure and allows continued clinical development, although future spending could still change the runway.
Late-Stage Pipeline ProgressProgress in a Phase 3 study and publication of BOND-003 Cohort C results indicate that cretostimogene is advancing through important clinical milestones. These developments could support regulatory filings and eventual commercialization if the program delivers favorable results.
Low LeverageMinimal debt relative to equity gives CG Oncology substantial financial flexibility for a clinical-stage business. Low leverage limits interest and refinancing burdens, allowing capital to remain focused on research, trials, and preparation for potential product commercialization.
Bears Say
No Commercial ProductCG Oncology currently lacks recurring product revenue because its lead candidate remains investigational. The business therefore depends on future regulatory approval, commercialization, or collaboration income before it can establish a durable operating revenue base.
Severe Operating LossesThe scale of operating losses is substantially larger than current revenue, showing that the existing cost base is not supported by commercial sales. Continued losses could increase reliance on external capital and make future profitability dependent on successful clinical execution.
Persistent Cash BurnLarge negative operating and free cash flow means CG Oncology is consuming cash to fund its current development model rather than self-financing operations. Sustained burn can shorten the practical value of the cash runway if research spending continues at a high level.
CG Oncology, Inc. News
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $35.80 and its highest was $80.97 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $5.31B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 25 days.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.664 by -$0.236.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.83.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 88,640,370 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.664. Following the earnings report the stock price went up 3.355%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CG Oncology, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.56 (17.23% Upside)
$92.56 (17.23% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 80%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 14.1%
Last 30 Days ▼ 14.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.01%
12-Months-Change
Fundamentals
Return on Equity
-25.20%
Trailing 12-Months
Asset Growth
54.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CG Oncology, Inc.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
CGON Stock 12 Month Forecast
Average Price Target
$92.56
▲(17.23% Upside)
Technical Analysis
Cogent Biosciences
―
Oric Pharmaceuticals
―
Relay Therapeutics
―
Tango Therapeutics
―
Erasca
―
Ownership Overview
2.35% Insiders
28.52% Mutual Funds
0.09% Other Institutional Investors
52.30% Public Companies and
Individual Investors